Table 1 Transplantation characteristics and immunosuppressive treatment
IL-2 plus | IL-2 minus | P | |
|---|---|---|---|
(N=149) | (N=83) | ||
Characteristics | |||
Recipient gender (male) | 105 (71%) | 59 (71%) | ns |
Recipient age (years); median (range) | 64.5 (14.9 to 82.8) | 65.8 (32.1 to 80.5) | ns |
Donor gender (male) | 100 (67%) | 38 (46%) | 0.002 |
Donor age (years); median (range) | 67.6 (60.2 to 89.0) | 65.5 (60.3 to 78.8) | 0.03 |
Time on dialysis (years); median (range) | 1.5 (0.0 to 6.3) | 1.4 (0.0 to 5.9) | ns |
Diabetic nephropathy | 14 (9%) | 8 (10%) | ns |
Vascular nephropathy | 40 (27%) | 32 (38%) | ns |
PRA positive recipients | 10 (7%) | 4 (5%) | ns |
Any HLA-A mismatch | 122 (82%) | 62 (75%) | ns |
Any HLA-B mismatch | 130 (87%) | 78 (94%) | ns |
Any HLA-DR mismatch | 82 (55%) | 41 (49%) | ns |
CMV-positive recipient | 125 (84%) | 57 (69%) | 0.01 |
CMV-positive donor | 121 (82%) | 72 (87%) | ns |
Cold ischemia time (hours); mean ± SD | 14.4 ± 5.1 | 13.3 ± 4.9 | ns |
Transplant year | |||
2004 | 0 | 24 | |
2005 | 6 | 26 | |
2006 | 6 | 26 | |
2007 | 43 | 6 | |
2008 | 46 | 0 | |
2009 | 48 | 1 | |
Initial CNI | |||
CsA | 126 (85%) | 80 (96%) | 0.008 |
Tacrolimus | 23 (15%) | 3 (4%) | 0.008 |
PRA, panel-reactive antibodies |